07.01.21
New Brunswick, NJ
www.jnj.com
Sales: $7.6 billion for personal care products
Corporate sales: $82.6 billion
Key Personnel
Alex Gorsky, chairman and chief executive officer; Thibaut Mongon, executive vice president, worldwide chairman, consumer health; Joseph J. Wolk, executive vice president, chief financial officer; Kathy Wengel, executive vice president and chief global supply chain officer
Major Products
Baby: Johnson’s. Beauty: Aveeno, Clean & Clear, Dabao, Johnson’s, Le Petite Marseillais, Lubriderm, Neutrogena, OGX, Sundown. Oral Care: Listerine
New Products
Baby: Cottontouch Creamy Baby Oil, Shea & Cocoa Butter Creamy Baby Oil, Moisturizing Almond Oil for Dry Skin; Beauty: Aveeno Hair Care, Aveeno Calm & Restore for Sensitive Skin, Neutrogena Clear Coverage, Neutrogena Healthy Scalp Clarify & Shine Scalp Scrub
Comments: Did you hear the news? J&J is spinning off its consumer products business from its pharma/medical device activities. The announcement was made on November 12, 2021.
In 2020, Johnson & Johnson was rightfully focused on things other than personal care. The company has played a critical role in the fight against COVID-19. In February, the US Centers for Disease Control approved J&J’s single-dose coronavirus vaccine for emergency use. At the time, observers considered it a breakthrough for reaching vulnerable and isolated Americans. The J&J vaccine didn’t require a follow-up shot, was more easily stored and became popular on college campuses, in door-to-door campaigns and with harder-to-reach communities that often struggle to access health care. Unfortunately, through mid-June only 11.8 million doses were administered in the US—that’s less than 4% of the total. States had warned for weeks that they may not find recipients for millions of doses that will soon expire, partly because the vaccine’s appeal dropped after it was linked to a rare but serious blood-clotting disorder and injections were paused for 10 days in April. The vaccine took another hit when regulators told Johnson & Johnson that it should throw out tens of millions of additional doses produced at a plant in Baltimore because they might be contaminated.
Last year, J&J’s corporate sales fell less than 1%, but the consumer health business dropped more. Skin health/beauty sales dropped 3.1% to $4.5 billion. J&J blamed the decline on negative COVID-19 related impacts and SKU rationalization partially offset by growth in e-commerce and new product innovation. Oral care sales rose 7.4% to $1.6 billion. The increase was due to Listerine mouthwash sales through e-commerce and club channels, increased stocking demand related to COVID-19 and new product launches in Asia Pacific. Baby care sales fell 9.4% to $1.5 billion. According to J&J, the decline was primarily due to COVID-19 related impacts, SKU rationalization and the Baby Center divestiture in the US, partially offset by strength in Aveeno baby.
Last year, J&J launched Neutrogena Studios, its first dedicated branded content studio. The project is designed to “create compelling and relevant stories that educate about the science behind skin health, celebrate beauty for all and inspire people to action.” Through feature documentaries and scripted shorts, Neutrogena Studios is trying to represent and illuminate diversity and inclusion, according to J&J.
For the first quarter of 2021, corporate sales rose nearly 8% to more than $22.3 billion. Skin health/beauty sales rose 4.1% to more than $1.1 billion. Oral care sales increased 5.7% to $417 million and baby care sales increased 7.7% to $389 million.
www.jnj.com
Sales: $7.6 billion for personal care products
Corporate sales: $82.6 billion
Key Personnel
Alex Gorsky, chairman and chief executive officer; Thibaut Mongon, executive vice president, worldwide chairman, consumer health; Joseph J. Wolk, executive vice president, chief financial officer; Kathy Wengel, executive vice president and chief global supply chain officer
Major Products
Baby: Johnson’s. Beauty: Aveeno, Clean & Clear, Dabao, Johnson’s, Le Petite Marseillais, Lubriderm, Neutrogena, OGX, Sundown. Oral Care: Listerine
New Products
Baby: Cottontouch Creamy Baby Oil, Shea & Cocoa Butter Creamy Baby Oil, Moisturizing Almond Oil for Dry Skin; Beauty: Aveeno Hair Care, Aveeno Calm & Restore for Sensitive Skin, Neutrogena Clear Coverage, Neutrogena Healthy Scalp Clarify & Shine Scalp Scrub
Comments: Did you hear the news? J&J is spinning off its consumer products business from its pharma/medical device activities. The announcement was made on November 12, 2021.
In 2020, Johnson & Johnson was rightfully focused on things other than personal care. The company has played a critical role in the fight against COVID-19. In February, the US Centers for Disease Control approved J&J’s single-dose coronavirus vaccine for emergency use. At the time, observers considered it a breakthrough for reaching vulnerable and isolated Americans. The J&J vaccine didn’t require a follow-up shot, was more easily stored and became popular on college campuses, in door-to-door campaigns and with harder-to-reach communities that often struggle to access health care. Unfortunately, through mid-June only 11.8 million doses were administered in the US—that’s less than 4% of the total. States had warned for weeks that they may not find recipients for millions of doses that will soon expire, partly because the vaccine’s appeal dropped after it was linked to a rare but serious blood-clotting disorder and injections were paused for 10 days in April. The vaccine took another hit when regulators told Johnson & Johnson that it should throw out tens of millions of additional doses produced at a plant in Baltimore because they might be contaminated.
Last year, J&J’s corporate sales fell less than 1%, but the consumer health business dropped more. Skin health/beauty sales dropped 3.1% to $4.5 billion. J&J blamed the decline on negative COVID-19 related impacts and SKU rationalization partially offset by growth in e-commerce and new product innovation. Oral care sales rose 7.4% to $1.6 billion. The increase was due to Listerine mouthwash sales through e-commerce and club channels, increased stocking demand related to COVID-19 and new product launches in Asia Pacific. Baby care sales fell 9.4% to $1.5 billion. According to J&J, the decline was primarily due to COVID-19 related impacts, SKU rationalization and the Baby Center divestiture in the US, partially offset by strength in Aveeno baby.
Last year, J&J launched Neutrogena Studios, its first dedicated branded content studio. The project is designed to “create compelling and relevant stories that educate about the science behind skin health, celebrate beauty for all and inspire people to action.” Through feature documentaries and scripted shorts, Neutrogena Studios is trying to represent and illuminate diversity and inclusion, according to J&J.
For the first quarter of 2021, corporate sales rose nearly 8% to more than $22.3 billion. Skin health/beauty sales rose 4.1% to more than $1.1 billion. Oral care sales increased 5.7% to $417 million and baby care sales increased 7.7% to $389 million.